Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.
Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors. Markman says only recently have papers been published on checkpoint inhibitors in the treatment of ovarian cancers, marking just how far behind research is on the topic compared to other cancers.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More